Upcoming GMP Unit for Advanced Intermediates
Upcoming GMP.
Chemco is expanding its pharmaceutical manufacturing capabilities through an upcoming GMP unit dedicated to advanced and penultimate intermediates. The facility is being developed to support customer programs linked to APIs including Acalabrutinib, Ambrisentan, Apixaban, Apremilast, Canagliflozin, Chlorthalidone, Dapagliflozin, Sotagliflozin, Doxofylline, Empagliflozin, Etoricoxib, Famotidine, Ibrutinib, Mirabegron, Tazemetostat, Ticagrelor and Praziquantel.
The new unit will support process development, technology transfer, scale-up and commercial manufacturing, with a focus on reliable execution, long-term supply and customer-specific intermediate programs.
Chemco is expanding its pharmaceutical manufacturing capabilities through an upcoming GMP unit dedicated to advanced and penultimate intermediates.
